A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

This study is testing a new experimental drug called Zotatifin to see if it can safely slow down or stop the growth of advanced solid tumors. It matters because researchers are looking for better ways to treat cancers that have not responded to standard therapies.

This trial is for adults with advanced solid tumors, which are abnormal tissue masses that are not blood cancers. Because the study involves specific drug combinations, doctors will check your cancer's genetic makeup to see if this treatment is a good match for you.

Participants will receive the study drug through an IV (a small tube in your vein). During the study, your medical team will monitor you closely to check how your body reacts to the medicine and to see if the treatment helps shrink or control the tumor.

The study is currently taking place at several clinics in Los Angeles and Newport Beach, California. The current status of the trial is not clearly listed, so you should contact these centers directly to see if they are still enrolling new patients.